Clotrimazole

證據等級: L5

預測適應症: 3 個

Clotrimazole: From Topical Antifungal to Vulvovaginitis

One-Sentence Summary

Clotrimazole is a broad-spectrum azole antifungal widely used globally for superficial fungal and yeast infections, including vulvovaginal candidiasis. The TxGNN model predicts it may be effective for Vulvovaginitis (ranked #2 by score; ranked #1 by actionable evidence), supported by 22 clinical trials and 20 publications — making it the most evidence-backed repurposing candidate in this pack. A secondary prediction for Acne (ranked #1 by TxGNN score) and Postmenopausal Atrophic Vaginitis (ranked #3) carry insufficient evidence at this time and are both recommended Hold.

Quick Overview

Item	Content
Original Indication	Topical antifungal (tinea, oropharyngeal candidiasis, vulvovaginal candidiasis — established global use; not yet registered in Saudi Arabia)
Predicted New Indication	Vulvovaginitis (Vulvovaginal Candidiasis)
TxGNN Prediction Score	99.59% (rank #6790 among all disease–drug pairs)
Evidence Level	L1 (multiple completed Phase 3/4 RCTs)
Saudi Arabia Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Clotrimazole is a synthetic imidazole antifungal that inhibits the fungal enzyme CYP51A1 (lanosterol 14α-demethylase), blocking ergosterol biosynthesis. Without ergosterol, the fungal cell membrane loses structural integrity and becomes permeable, leading to cell death. This mechanism is direct and well-established against Candida species — including C. albicans, C. glabrata, and C. tropicalis — which are responsible for the overwhelming majority of vulvovaginal candidiasis (VVC) cases.

Vulvovaginitis is not a new predicted use in the true sense: vulvovaginal candidiasis accounts for 20–25% of all vulvovaginitis and is one of the most important globally approved indications for clotrimazole. The TxGNN model correctly identifies this mechanistic alignment, and the evidence base (multiple Phase 4 RCTs, a post-marketing study of 1,033 patients, and >20 publications) confirms that this prediction is well-grounded in established pharmacology.

The key repurposing opportunity here is not mechanism discovery but market authorization: clotrimazole carries a decades-long global safety record for vulvovaginal candidiasis and is currently absent from the Saudi Arabian (SFDA) market. Registering it would fill an existing therapeutic gap in gynecological fungal infection management.

Clinical Trial Evidence

Primary indication: Vulvovaginitis / Vulvovaginal Candidiasis — top 10 trials by relevance and quality

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02180828	Phase 4	Completed	240	Head-to-head RCT: Clotrimazole vaginal tablet vs Fluconazole oral for severe vulvovaginal candidiasis — core direct efficacy and safety evidence
NCT03599323	N/A	Completed	1,033	Post-marketing non-interventional safety study of Empecid L Cream (Clotrimazole 1%) in vaginal yeast infection under pharmacist guidance; large real-world safety dataset
NCT00755053	Phase 3	Completed	466	Investigator-blinded active-controlled study: Clotrimazole ovule 500 mg vs Clotrimazole vaginal tablet 500 mg; demonstrated non-inferiority of new formulation
NCT00313131	Phase 3	Completed	1,524	Large RCT in West Africa comparing single-dose tinidazole + fluconazole vs metronidazole + vaginal clotrimazole (3 days) for syndromic vaginal discharge management
NCT03562156	Phase 3	Completed	438	Double-blind, placebo-controlled Phase 3 evaluating oteseconazole for recurrent VVC; large-scale, rigorous design confirming the burden of RVVC and standard of care context
NCT04699240	Phase 4	Completed	140	RCT: Clotrimazole vaginal tablets ± oral Lactobacillus for prevention of recurrent VVC; Clotrimazole used as active comparator/backbone treatment
NCT02242695	Phase 4	Completed	150	Head-to-head: 10 mg dequalinium chloride vs 100 mg clotrimazole vaginal tablet in VVC; evaluated clinical efficacy, safety, and patient satisfaction
NCT06835361	Phase 2/3	Recruiting	264	International open-label RCT comparing Clotrimazole + Lactulose vaginal suppositories vs Clotrimazole monotherapy (Canesten®) in candidal vulvovaginitis
NCT01230814	Phase 2	Completed	234	Double-blind RCT of monthly metronidazole + miconazole suppositories vs placebo for preventing recurrent VVC; same-class comparator context
NCT04292704	N/A	Unknown	205	Protocol for RCT of fractional CO2 laser as consolidation treatment in recurrent VVC; antifungal treatment (including azoles) serves as standard backbone

Literature Evidence

Top 10 publications by study type priority — RCT first, then reviews, then mechanistic

PMID	Year	Type	Journal	Key Findings
2644595	1989	RCT	Obstetrics and Gynecology	Prospective double-blind RCT (n=42): Clotrimazole 500 mg vaginal suppositories once weekly × 2 weeks achieved 90.4% clinical remission in recurrent VVC; monthly prophylaxis thereafter significantly reduced recurrence
3895960	1985	RCT	Am J Obstet Gynecol	Open randomized study (n=199): single vaginal tablet 500 mg vs 6-day 100 mg clotrimazole in candidal vulvovaginitis; both regimens achieved equivalent mycologic cure rates
39824974	2025	RCT	Scientific Reports	Triple-blinded equivalence RCT (n=126): Mycozin vs Clotrimazole 1% cream for vaginal candidiasis; confirmed clotrimazole as effective standard comparator for symptom relief
41765149	2026	RCT	Complementary Therapies in Medicine	RCT comparing Prangos ferulacea vaginal cream vs clotrimazole for VVC; clotrimazole arm demonstrated robust clinical and laboratory cure — used as active gold-standard comparator
30565745	2019	RCT	Mycoses	Randomised trial in recurrent VVC: probiotics + lactoferrin vs maintenance clotrimazole; supports clotrimazole's role as maintenance therapy standard in RVVC management
24863842	2014	Review	J Applied Microbiology	Comprehensive review: "Clotrimazole as a pharmaceutical — past, present and future." Covers antifungal mechanism (ergosterol pathway), established indications (tinea, VVC, oropharyngeal candidiasis), and emerging pharmacological targets (IK1 potassium channel)
39362128	2024	Meta-analysis	Eur J Obstet Gynecol Reprod Biol	Bayesian network meta-analysis of pharmacological maintenance therapy for RVVC; synthesizes evidence for oral/topical agents including clotrimazole at 24- and 48-week endpoints
39419780	2024	Cohort/Mechanistic	J Applied Microbiology	Prospective study: clotrimazole treatment of VVC shifts vaginal bacteriome and lipid metabolism; mechanistic insight into how clotrimazole restores vaginal microecological balance
21774671	2011	Review	J Women's Health	Review of boric acid for recurrent VVC (resistant to azoles including clotrimazole); contextualizes non-albicans Candida resistance as a gap where clotrimazole alone may be insufficient
7482105	1995	Clinical Trial	Sexually Transmitted Diseases	Comparative study: fluconazole vs clotrimazole for VVC; addresses compliance advantage of oral route, while confirming comparable antifungal efficacy of topical clotrimazole

Saudi Arabia Market Information

Clotrimazole is currently not registered with the Saudi Food and Drug Authority (SFDA). No licenses or approved products are on record.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	Not applicable	—	No registered products in Saudi Arabia

Note: Clotrimazole holds regulatory approvals in over 100 countries, including multiple formulations (vaginal tablets, creams, ovules, topical cream) for vulvovaginal candidiasis and dermatophyte infections. The absence of SFDA registration represents a market gap rather than a safety or efficacy concern.

Safety Considerations

Detailed package insert data (warnings, contraindications) was not available through the data sources queried for this Evidence Pack. Please refer to the package insert for full safety information.

Known drug class context (from published literature): Clotrimazole is a topically applied agent with minimal systemic absorption, contributing to its favorable safety profile. The Empecid L post-marketing study (n=1,033; NCT03599323) confirmed no unexpected safety signals in real-world community use. Azole-class resistance in non-albicans Candida species (e.g., C. glabrata) is an acknowledged clinical limitation.

Additional TxGNN Predictions — Supporting Information

Prediction #1 (TxGNN Rank): Acne — Hold

Item	Detail
TxGNN Score	99.86%
Evidence Level	L4 (preclinical/mechanistic only)
Clinical Trials	1 (SUSPENDED, combination product, no usable data)
Literature	0 publications identified
Mechanistic Link	Indirect: Clotrimazole may suppress Malassezia furfur (a comorbid pathogen in some acne presentations) and has minor anti-inflammatory activity via IK1 potassium channel blockade. However, the primary drivers of acne (P. acnes infection, sebaceous gland obstruction, androgens) are outside Clotrimazole's pharmacological target range.

Prediction #3 (TxGNN Rank): Postmenopausal Atrophic Vaginitis — Hold

Item	Detail
TxGNN Score	99.46%
Evidence Level	L5 (model prediction only)
Clinical Trials	1 (UNKNOWN status, unrelated CO2 laser study)
Literature	0 publications identified
Mechanistic Link	Very weak: Postmenopausal atrophic vaginitis (GSM) is driven by estrogen deficiency, not fungal overgrowth. Clotrimazole cannot address the root cause. High TxGNN score likely reflects disease feature overlap with vulvovaginitis.

Conclusion and Next Steps

Decision: Proceed with Guardrails (for Vulvovaginitis / Vulvovaginal Candidiasis)

Rationale: Clotrimazole has one of the most robust evidence bases among azole antifungals for vulvovaginal candidiasis, backed by multiple completed Phase 3/4 RCTs (including head-to-head comparisons with fluconazole), a 1,033-patient post-marketing safety study, and over 35 years of published clinical trial literature — fully meeting L1 criteria. Its absence from the Saudi Arabian market represents a registration gap, not a safety or efficacy unknown.

To proceed, the following is needed:

SFDA registration dossier: Compile CMC data, clinical efficacy dossier (existing global RCTs are sufficient), and local pharmacovigilance plan for submission
Package insert localization: Obtain and translate official warnings, contraindications, and dosing information for Saudi patient population (data gap DG001)
Formulation decision: Confirm preferred registration route — vaginal tablet (500 mg single dose or 100 mg × 6 days), cream (1%), or ovule (500 mg) — based on SFDA preference and supply chain considerations
Resistance monitoring plan: Establish surveillance for non-albicans Candida species resistant to azoles, as these represent the main clinical limitation of clotrimazole therapy
MOA documentation (DG002): Formally document CYP51A1 inhibition mechanism in submission package for SFDA scientific review
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.